Abstract

Pituitary gigantism is an extremely rare disorder: the incidence of pituitary tumors in children is approximately 0.1 in one million, and only about 1 to 10% of the pituitary tumors secrete the GH in childhood. Gigantism should be suspected if the patient's height is 3 standard deviations above the normal average height or 2 standard deviations above the corrected height of parents. When pituitary gigantism is suspected, the clinician should consider the presence of disorders, known to be associated with the GH-secreting pituitary tumors, including the McCune Albright syndrome (MAS), Carney complex (CNC), multiple endocrine neoplasia, types 1 and 4 (MEN 1, MEN 4), Familial isolated pituitary adenoma (FIPA), the paraganglioma, pheochromocytoma and pituitary adenoma association (PAA) due to succinate dehydrogenase defects, and X-linked acrogigantism (X-LAG). The molecular genetics of the AIP-associated FIPA, MAS, CNC, and MEN 1 has been extensively studied and reviewed, especially in children and young adults. The GH-secreting adenomas seem to be more invasive and aggressive in childhood than in adulthood. Data on a rare disease — gigantism combined with phenotypic signs of acromegaly in a young patient are presented. Clinical and laboratory parameters, data of histological and genetic analysis are described. Genetic analysis performed by AIP gene by Sequencing, proved a rare mutation in the locus of exons 1-6 of the AIP gene. The presented clinical case describes a rare fact of the AIP-gene mutation in the p.Cys238Tyr locus, which is associated with the occurrence of a giant pituitary adenoma in childhood. Aggressive growths of the pituitary tumor, its high proliferative and hormonal activity, clinical manifestations of gigantism in combination with severe phenotypic signs of acromegaly have also been noticed. Resistance to the therapy with somatostatin analogs has been revealed in this case. Considering the absence of genetic predisposition to a pituitary adenoma in the patient, this case can be regarded as a sporadic pituitary adenoma variant due to the abnormal AIP-gene expression and the disturbance of regulation during tumorigenesis.

Highlights

  • SUBJECT AND METHODSDiagnosis of acromegaly is based on the Consensus Statement (2018) [1]. Chemilu­mi­ nes­cence has been used to detect the levels of serum growth hormone (GH) (ng/ml), insulin-like growth factor-I (IGF-I), prolactin (PRL), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), fol­licle-stimulating hormone (FSH), free thyro­ xine (fT4) using the Biomerica Immunoassay System (USA)

  • Is a systemic, chronic, and slowly developing disease, resulting from the excess of the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in persons with the complete physiological growth

  • When pituitary gigantism is suspec­ ted, the clinician should consider the presence of disorders, known to be associated with the GH-secreting pituitary tumors, including the McCune Albright syndrome (MAS) [6], Carney complex (CNC), multiple endocrine neoplasia, types 1 and 4 (MEN 1, MEN 4) [7], Familial isolated pituitary adenoma (FIPA), the paraganglioma, pheochromocytoma and pituitary adenoma association (PAA) due to succinate dehydrogenase defects, and X-linked acrogigantism (X-LAG) [8]

Read more

Summary

SUBJECT AND METHODS

Diagnosis of acromegaly is based on the Consensus Statement (2018) [1]. Chemilu­mi­ nes­cence has been used to detect the levels of serum GH (ng/ml), insulin-like growth factor-I (IGF-I), prolactin (PRL), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), fol­licle-stimulating hormone (FSH), free thyro­ xine (fT4) using the Biomerica Immunoassay System (USA). A 18-year-old boy was admitted to our clinic after neurosurgery treatment in Romodanov Institute of Neurosurgery, the NAMS of Ukraine His height was 203.5 cm (+ 3.7 SDS), body weight 97.3 kg (+ 5.5 SDS), and his feet length was 36.5 cm (EU size 53). Acceleration of his growth velocity started from the age of 14 yrs. The pituitary MRI scan, performed 6 months after surgery, showed pituitary adenoma of a significantly reduced size: residual tumor has been determined in the suprasellar region only, mainly to the left of the middle line, with a slight chiasm compression and the ventricle III bottom involvement. Cytoplasmic and transmembrane expression of somatotropes is present in 90 % of cells

After surgery
Findings
DISCUSSION
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call